These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8920707)

  • 1. International scientific conference on viral safety and evaluation of viral clearance from biopharmaceutical products.14-16 June 1995, Bethesda, MD, USA.
    Sanhueza S
    Vaccine; 1996 Feb; 14(3):244-6. PubMed ID: 8920707
    [No Abstract]   [Full Text] [Related]  

  • 2. Viral Safety and Evaluation of Viral Clearance from Biopharmaceutical Products. Proceedings of a meeting. Bethesda, Maryland, USA, June 14-16, 1995.
    Dev Biol Stand; 1996; 88():1-342. PubMed ID: 9119120
    [No Abstract]   [Full Text] [Related]  

  • 3. Viral safety of biological products in WHO policy.
    Grachev VP
    Dev Biol Stand; 1991; 75():241-6. PubMed ID: 1794628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of approaches to viral safety issues for biological products.
    Lubiniecki AS
    PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current testing methods and challenges for detection of adventitious viruses.
    Khan AS
    PDA J Pharm Sci Technol; 2011; 65(6):627-33. PubMed ID: 22294589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Issues related to harmonization of testing requirements for viral safety.
    Hayakawa T
    Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case study of apparent virus contamination in biopharmaceutical product at centocor.
    Hendricks LC; Vacante DA
    PDA J Pharm Sci Technol; 2011; 65(6):612-3. PubMed ID: 22294583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory approaches for control of viral contamination of vaccines.
    McClenahan S; Uhlenhaut C; Krause PR
    PDA J Pharm Sci Technol; 2011; 65(6):557-62. PubMed ID: 22294577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk mitigation strategies for viral contamination of biotechnology products: consideration of best practices.
    Rosenberg AS; Cherney B; Brorson K; Clouse K; Kozlowski S; Hughes P; Friedman R
    PDA J Pharm Sci Technol; 2011; 65(6):563-7. PubMed ID: 22294578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products.
    Gombold J; Karakasidis S; Niksa P; Podczasy J; Neumann K; Richardson J; Sane N; Johnson-Leva R; Randolph V; Sadoff J; Minor P; Schmidt A; Duncan P; Sheets RL
    Vaccine; 2014 May; 32(24):2916-26. PubMed ID: 24681273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of biological products prepared from mammalian cell culture. In-process testing for viral agents.
    Dev Biol Stand; 1998; 93():130-1. PubMed ID: 9737389
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification and remediation of a cell culture virus contamination.
    Jones N
    PDA J Pharm Sci Technol; 2011; 65(6):615. PubMed ID: 22294585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of the second international conference on next generation sequencing for adventitious virus detection in biologics for humans and animals.
    Khan AS; Blümel J; Deforce D; Gruber MF; Jungbäck C; Knezevic I; Mallet L; Mackay D; Matthijnssens J; O'Leary M; Theuns S; Victoria J; Neels P
    Biologicals; 2020 Sep; 67():94-111. PubMed ID: 32660862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral safety of biological products and the concept of validation.
    Horaud F
    Dev Biol Stand; 1996; 88():19-24. PubMed ID: 9119135
    [No Abstract]   [Full Text] [Related]  

  • 16. Quality control of bovine serum used for vaccine production.
    Mareschal JC
    Dev Biol Stand; 1999; 99():61-8. PubMed ID: 10404877
    [No Abstract]   [Full Text] [Related]  

  • 17. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
    Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
    PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Massively parallel sequencing: a new tool in virus discovery and vaccine safety.
    Onions D
    Bull Mem Acad R Med Belg; 2011; 166(10-12):404-6. PubMed ID: 23082505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA post-approval expectations for adventitious virus contamination prevention.
    Friedman RL
    PDA J Pharm Sci Technol; 2011; 65(6):698-712. PubMed ID: 22294604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WHO Expert Committee on Biological Standardization. Forty-sixth Report.
    World Health Organ Tech Rep Ser; 1998; 872():i-vii, 1-90. PubMed ID: 9615608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.